Science-37 Clinical Trial Management System
(Redirected from Science 37's CTMS)
Jump to navigation
Jump to search
A Science-37 Clinical Trial Management System is a Clinical Trial Management System that is designed by Science 37 to support and manage clinical research through Agile Clinical Trials Platform.
- Example(s):
- …
- Counter-Example(s):
- See: Clinical Research, Decentralized Clinical Trial, Clinical Trial Protocol, Clinical Trial Participant, Clinical Trial Phase, Electronic Data Capture (EDC) System, Clinical Data Management System (CDMS), Electronic Clinical Outcome Assessment (eCOA) System, Direct-to-Patient Digital Clinical Trial, Patient Monitoring System (PMS), Patient Recruitment System (PRS), Cloud-based Digital Patient Recruitment and Engagement Platform.
References
2021a
- (Science 37, 2021) ⇒ https://www.science37.com/Operating-System Retrieved:2021-12-19.
- QUOTE: Science 37’s specialized networks work seamlessly with our technology platform to orchestrate decentralized clinical trials. Our networks include patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices. These networks continue to grow to power increasingly complex decentralized clinical trial designs.
2021b
- (AABME-ASME, 2021) ⇒ https://aabme.asme.org/posts/technologies-driving-clinical-trial-management Retrieved:2021-12-19.
- QUOTE: Science 37 focuses on siteless clinical trials-direct-to-patient studies—by leveraging cloud computing and telehealth to collect evidence on a therapy. The company uses telemedicine and decentralized physician networks to design an integrated clinical study where real-time patient data is collected to shape outcomes. Its cloud-based mobile research platform, the Network Oriented Research Assistant (NORA), manages clinical trials across all stages—screening, recruiting, remote monitoring and data collection. The company is able to address pain points such as adding diversity by widening the patient pool through remote monitoring. By continuously engaging with trial participants using a variety of communication channels and doing it at a time and place convenient to the patient, they were able to improve patient retention through the end of a study. Leading biopharmaceutical companies such as UCB, Otsuka Pharmaceuticals and Novartis are working with Science 37 to accelerate clinical trials by bringing new drugs to patients in a shorter time. Novartis, for example, in a partnership announced in March, plans to use the platform for U.S. trials in neuroscience, oncology and dermatology that will begin this year.